neoag
Neoantigen × AI
Daily research signal
TOPICS / MODALITY

mRNA vaccines

Messenger-RNA platforms that encode a patient's neoantigens and are translated into protein in vivo — the modality behind Moderna/Merck's mRNA-4157 and BioNTech's autogene cevumeran.

Topic10 items2026-05-29 – 2026-06-03
Modalities
Peptide vaccines27mRNA vaccines10Dendritic-cell vaccines9TCR & T-cell receptor8DNA vaccines5Viral-vector vaccines3Shared & off-the-shelf3Oncolytic viruses1Lipid nanoparticles1
01
AI / Methods

mRNA vaccines in gastrointestinal cancers: Mechanistic basis, translational challenges, and emerging therapeutic strategies.

A review of mRNA vaccines in gastrointestinal cancers highlights their rapid, cell-free manufacturing and modular design as key advantages over conventional platforms. However, efficacy is constrained by tumor heterogeneity and immunosuppressive microenvironments, with antigen selection strategies for personalized neoantigens remaining a critical variable for immune specificity and therapeutic variability.

europepmc · brief 2026-06-03 · published 2026-05-01
02
Clinical

Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results - Nature

Interim results from a Phase 1 trial of an individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine show activity in advanced metastatic solid tumors. This highlights the diversification of delivery vectors beyond standard mRNA, potentially offering improved immunogenicity or manufacturing advantages.

Viral-vector vaccines
news · brief 2026-06-01 · published 2022-08-15
04
Clinical

To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors

Shenzhen Xinhe Biomedical has initiated a Phase 1 trial for XH001, a personalized mRNA tumor neoantigen vaccine, as adjuvant therapy for high-risk recurrent solid tumors. This entry marks the expansion of Chinese biotech players into the personalized vaccine space, focusing on post-surgical recurrence prevention.

clinicaltrials · brief 2026-06-01 · published 2026-05-19
05
AI / Methods

A priority index-based computational medicine framework (PimRNA) for prioritising personalised mRNA cancer vaccines

Researchers present PimRNA, a computational framework that prioritizes personalized mRNA vaccines by integrating neoantigen identification with gene interaction network analysis. This addresses a key translational gap by moving beyond simple HLA binding affinity to consider biological context and mRNA design constraints like codon usage.

biorxiv · brief 2026-06-01 · published 2026-05-29
07
Clinical

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

Shanghai Jiao Tong University School of Medicine is recruiting for a trial of mRNA-0523-L001, an individualized mRNA neoantigen vaccine, in advanced endocrine tumors including adrenal corticocarcinoma and medullary thyroid carcinoma. The study evaluates safety, tolerability, and preliminary efficacy, including T-cell responses and objective response rates, in patients with failed or no standard treatments.

clinicaltrials · brief 2026-05-30 · published 2026-04-09
08
Clinical

Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection

Yifan Wang is leading a Phase I/II trial for iNeo-Vac-R01, an individualized mRNA therapeutic based on tumor neoantigens. The study evaluates safety for adjuvant treatment in patients with biliary malignant tumors after radical resection, marking a move toward mRNA-based personalization in hepatobiliary cancers.

clinicaltrials · brief 2026-05-30 · published 2026-02-03
09
Clinical

Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors

West China Hospital has launched a Phase I dose-escalation study for PAN-NeoVax, an AI-designed pan-cancer neoantigen mRNA vaccine delivered via intratumoral injection. The trial targets advanced solid tumors post-second-line therapy, utilizing a 3+3 design to assess safety and preliminary efficacy of lipid nanoparticle-formulated mRNA.

Lipid nanoparticles
clinicaltrials · brief 2026-05-29 · published 2026-05-11
10
AI / Methods

Neoantigen-based T cell vaccines design strategies, therapeutic barriers, and clinical advances.

A comprehensive review in EuropePMC synthesizes the current state of neoantigen-based T cell vaccines, covering design strategies, therapeutic barriers, and clinical advances. The article examines mechanisms across mRNA, peptide, and dendritic cell platforms, highlighting synergies with checkpoint blockade and the challenges of immunosuppressive tumor microenvironments.

Peptide vaccinesDendritic-cell vaccines
europepmc · brief 2026-05-29 · published 2026-05-01
Where nextAll topicsToday’s briefTrials tracker